Innate and adaptive immunity play crucial roles in suppressing tumor progression ([@pky058-B1],[@pky058-B2]). In colorectal carcinomas, high-level infiltrates of CD3^+^ cells, CD8^+^ cells, and CD45RO (PTPRC)^+^ cells in the tumor microenvironment have been associated with longer patient survival ([@pky058-B3]). Emerging evidence indicates that immunotherapies targeting immune checkpoint molecules such as *PDCD1* (programmed cell death 1, PD-1) and *CD274* (*PDCD1* ligand 1, PD-L1) can be effective in treating several cancer types ([@pky058-B8]), including colorectal cancer with high-level microsatellite instability (MSI) ([@pky058-B9],[@pky058-B10]). Elucidating the interplay between tumor cells and the immune system is of considerable importance to further improve the efficacy of immunoprevention and immunotherapy strategies for cancer ([@pky058-B11]).

High-level physical activity has been associated with lower incidence and mortality of colorectal cancer ([@pky058-B18]). Evidence suggests that physical activity may prolong colorectal cancer patient survival through decreasing chronic inflammation in the tumor microenvironment and enhancing the T cell-mediated antitumor immune response ([@pky058-B29]). Colorectal cancer consists of a heterogeneous group of neoplasms due to complex interactions with environmental factors, host immune cells, and transformed cells ([@pky058-B1],[@pky058-B33]). We considered that tumors that had progressed despite the presence of higher T cell reaction might have developed mechanisms to escape immune surveillance; such tumors with higher immune reaction might exhibit refractoriness to immunomodulatory effects of physical activity after cancer diagnosis. We therefore hypothesized that survival benefits associated with increased physical activity levels might be stronger for tumors with lower T cell reaction than for tumors with a higher reaction.

To test our hypothesis, we used a molecular pathological epidemiology database derived from two large prospective cohort studies in the United States with data on physical activity levels after colorectal cancer diagnosis, tumor molecular and immune features, and survival outcomes. We examined the interactive prognostic association of postdiagnosis physical activity levels and tumor-infiltrating T cells.

Methods
=======

Study Population
----------------

We examined data from two large prospective cohort studies in the United States: the Nurses' Health Study (NHS, 121 701 women ages 30--55 years followed since 1976) and the Health Professionals Follow-up Study (HPFS, 51 529 men ages 40 to 75 years followed since 1986) ([@pky058-B34]). Study participants have been sent follow-up questionnaires biennially to update information on demographics, lifestyle factors, and medical history and to report newly diagnosed diseases including colorectal cancer. The follow-up rate has been more than 90% for each questionnaire cycle in both cohorts. The National Death Index was used to ascertain deaths of study participants and identify patients with unreported lethal colorectal cancer. Informed consent was obtained from all participants at study enrollment. This study was approved by the Human Subjects Committees at Harvard T.H. Chan School of Public Health and Brigham and Women's Hospital (Boston, MA).

We included 470 colorectal cancer cases with available data on postdiagnosis physical activity levels and T cell densities in tumor tissue among participants diagnosed with colorectal cancer through 2008. We included both colon and rectal carcinoma cases based on the colorectal continuum model ([@pky058-B35]). Patients were followed until death or end of follow-up (June 30, 2014 for the NHS; January 1, 2014 for the HPFS), whichever came first. Study physicians, blinded to exposure data, reviewed medical records of patients diagnosed with colorectal cancer to collect data on tumor characteristics and to identify causes of death for deceased patients. We collected formalin-fixed paraffin-embedded tumor tissue samples from hospitals throughout the United States where participants with colorectal carcinoma underwent tumor resection. A single pathologist (SO), blinded to other data, conducted a central review of hematoxylin and eosin-stained tissue sections of all colorectal carcinoma cases and collected data on histopathological characteristics, including tumor differentiation and four lymphocytic reaction patterns (Crohn-like lymphoid reaction, peritumoral lymphocytic reaction, intratumoral periglandular reaction, and tumor-infiltrating lymphocytes) ([@pky058-B36]).

Assessment of Physical Activity Levels
--------------------------------------

In the NHS and HPFS, leisure-time physical activity has been assessed biennially since 1986 using a self-administered physical activity questionnaire, which was validated against physical activity diaries in which the participants documented the duration of time spent in activities as previously described ([@pky058-B37]). Participants reported the duration of physical activity for each component of physical activity. Based on this information, we calculated a metabolic equivalent task score (METS) ([@pky058-B38]), which was defined as the ratio of the metabolic rate of specific activities to the resting metabolic rate ([@pky058-B39],[@pky058-B40]). We summed up the METS for each activity to obtain the total METS-hours/week. To avoid the period of active anti-cancer treatment, we used questionnaire data reported between 6 and 48 months after diagnosis of colorectal cancer. To minimize the bias arising from reduced physical activity due to the progression of disease, physical activity was evaluated at the earliest time period after the diagnosis of colorectal cancer. Taking into account sex differences in lifestyle and physical activity, we classified physical activity levels into sex-specific quartiles ([@pky058-B39],[@pky058-B40]).

Immunohistochemistry
--------------------

We constructed tissue microarrays from colorectal cancer tissue blocks ([@pky058-B41]) and conducted immunohistochemistry for CD3, CD8, CD45RO, and FOXP3, as previously described ([@pky058-B7]). We used an automated scanning microscope and the Ariol image analysis system (Genetix, CA) to measure T cell densities (cells/mm^2^) in tumor tissue. We assessed up to four tissue microarray cores from each tumor and calculated the average density of each tumor-infiltrating T cell subset. If applicable, we categorized T cell densities into low vs high by the median value.

Immunohistochemical analyses for CTNNB1 (beta-catenin) expression ([@pky058-B42]), PTGS2 (cyclooxygenase-2) expression ([@pky058-B39]), and *IRS1* expression ([@pky058-B40]) were performed using a mouse anti-CTNNB1 antibody (BD Transduction Laboratories, CA), anti-PTGS2 antibody (Cayman Chemical, MI), and anti-IRS1 antibody (Millipore, Billerica, MA), respectively.

Analyses of Microsatellite Instability, DNA Methylation, and *KRAS*, *BRAF*, and *PIK3CA* Mutations
---------------------------------------------------------------------------------------------------

DNA was extracted from archival formalin-fixed, paraffin-embedded tumor tissue. We determined MSI status using 10 microsatellite markers (D2S123, D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56, D18S67, and D18S487), as previously described ([@pky058-B43]). We defined MSI-high as the presence of instability in 30% or more of the markers, and non-MSI-high as instability in less than 30% of the markers. Using bisulfite-treated DNA, we quantified DNA methylation in eight CpG island methylator phenotype (CIMP)-specific promoters (*CACNA1G*, *CDKN2A*, *CRABP1*, *IGF2*, *MLH1*, *NEUROG1*, *RUNX3*, and *SOCS1*) and in long interspersed nucleotide element-1 (LINE-1) ([@pky058-B44],[@pky058-B45]). We defined CIMP-high as the presence of six or more methylated promoters and CIMP-low/negative as five or fewer methylated promoters ([@pky058-B45]). We conducted polymerase chain reaction and pyrosequencing targeted for *KRAS* (codons 12, 13, 61, and 146) ([@pky058-B46]), *BRAF* (codon 600) ([@pky058-B43]), and *PIK3CA* (exons 9 and 20) ([@pky058-B47]).

Statistical Analysis
--------------------

Detailed information on statistical methods is included in [Supplementary Methods](#sup1){ref-type="supplementary-material"} (available online). All statistical analyses were performed using SAS software (version 9.4, SAS Institute, Cary, NC), and all *P* values were two-sided. Our primary hypothesis testing was assessment of a statistical interaction (using the Wald test on the cross-product) between postdiagnosis physical activity levels (the median value of each decile category) and T cell densities in tumor tissue (the median value of each decile category) in the Cox proportional hazards regression model for colorectal cancer-specific mortality analysis. Variables for physical activity and T cell densities were treated as decile categorical variables to reduce the influential effect of a few arbitrary cutoff points. In our primary hypothesis testing on new discoveries, we used the α level of 0.005 ([@pky058-B48]). All other analyses including evaluations of stratum-specific hazard ratios (HRs) and survival curves represented secondary analyses. In our secondary and other exploratory analyses, we recognized multiple comparisons associated with those analyses and used the α level of 0.005. Outcome endpoints were colorectal cancer-specific mortality and overall mortality. Survival time was defined as the time since colorectal cancer diagnosis to death or the end of follow-up, whichever came first, and was left-truncated at the time of the first postdiagnosis questionnaire return.

To reduce bias due to the availability of postdiagnosis questionnaire data, the inverse probability weighting (IPW) method was used in all survival analyses ([@pky058-B49]). We estimated the probability of questionnaire return after colorectal cancer diagnosis using the multivariable logistic regression model as previously described ([@pky058-B49]) and used the inverse probability to weight each patient. When we performed sex-stratified IPW-adjusted Cox regression analyses without truncation of weight, the results remained consistent (data not shown). Multivariable sex-stratified Cox proportional hazards models initially included age at diagnosis, year of diagnosis, prediagnosis physical activity, postdiagnosis body mass index, history of colorectal cancer in any first-degree relatives, tumor location, tumor differentiation, disease stage, MSI status, CIMP, LINE-1 methylation level, *BRAF* mutation, *KRAS* mutation, *PIK3CA* mutation, nuclear CTNNB1 expression, PTGS2 expression, and *IRS1* expression. A backward elimination was performed with a threshold of *P* equals .05 to select variables for the final models. We also estimated HRs for a quartile-unit increase of postdiagnosis physical activity levels in strata of levels of T cell densities using a re-parameterization of the interaction term in a single regression model ([@pky058-B45]). The cases with missing data were included in the majority category of a given categorical covariate to limit the degrees of freedom of the models. For cases with missing data on LINE-1 methylation level (2.1%) and *IRS1* expression (12.0%), we assigned a separate indicator variable for each variable. We confirmed that excluding cases with missing information in any of the covariates did not alter our results substantially (data not shown). The proportionality of hazards assumption was evaluated using a time-dependent variable, which was the cross-product of the postdiagnosis physical activity variable and survival time (*P* \> .05). Results of Cox regression analyses without IPW, which were similar to those with IPW, are shown in [Supplementary Table 1](#sup1){ref-type="supplementary-material"} (available online). Survival probabilities were estimated using the IPW-adjusted Kaplan-Meier method and compared using the weighted log-rank test ([@pky058-B52]).

Results
=======

We included 470 colorectal cancer cases with available data on postdiagnosis physical activity levels and T cell densities in tumor tissue. [Table 1](#pky058-T1){ref-type="table"} summarizes the clinical, pathological, and molecular characteristics of colorectal cancer cases according to quartiles of postdiagnosis physical activity levels. During the median follow-up time of 17.3 years (interquartile range = 14.9 to 20.6 years) for all censored cases, there were 275 deaths from any cause, including 100 colorectal cancer-specific deaths. Postdiagnosis physical activity levels were associated with colorectal cancer-specific mortality overall ([Table 2](#pky058-T2){ref-type="table"}).

###### 

Clinical, pathological, and molecular characteristics of colorectal cancer cases according to postdiagnosis physical activity levels

                                                                                         Postdiagnosis physical activity levels                                         
  -------------------------------------------------------------------- ----------------- ---------------------------------------- ----------------- ------------------- --------------------
  Postdiagnosis physical activity levels (METS-h/wk), median (range)                                                                                                    
   Female (n = 252, NHS)                                               7.3 (0--157.9)    0.7 (0--2.2)                             3.7 (2.3--7.2)    10.2 (7.3--16.9)    36.0 (17.0--157.9)
   Male (n = 218, HPFS)                                                15.4 (0--155.9)   1.0 (0--4.9)                             8.6 (5.0--15.3)   23.0 (15.4--34.9)   57.3 (35.0--155.9)
  Mean age ± SD, y                                                     67.8 ± 8.0        69.4 ± 8.7                               68.3 ± 7.9        67.0 ± 8.0          66.5 ± 7.2
  Year of diagnosis                                                                                                                                                     
   1995 or before                                                      209 (44%)         41 (36%)                                 61 (50%)          50 (43%)            57 (48%)
   1996 to 2000                                                        194 (41%)         56 (49%)                                 45 (37%)          47 (40%)            46 (39%)
   2001 to 2008                                                        67 (14%)          17 (15%)                                 15 (12%)          20 (17%)            15 (13%)
  Family history of colorectal cancer in first-degree relative(s)                                                                                                       
   Absent                                                              369 (79%)         89 (78%)                                 89 (74%)          100 (85%)           91 (77%)
   Present                                                             101 (21%)         25 (22%)                                 32 (26%)          17 (15%)            27 (23%)
  Body mass index                                                                                                                                                       
   \<25 kg/m^2^                                                        209 (48%)         41 (41%)                                 55 (48%)          58 (53%)            55 (51%)
   25 to 29.9 kg/m^2^                                                  156 (36%)         35 (35%)                                 42 (37%)          37 (34%)            42 (39%)
   ≥30 kg/m^2^                                                         68 (16%)          25 (25%)                                 17 (15%)          15 (14%)            11 (10%)
  Tumor location                                                                                                                                                        
   Cecum                                                               89 (19%)          27 (24%)                                 21 (17%)          19 (16%)            22 (19%)
   Ascending to transverse colon                                       139 (30%)         29 (25%)                                 34 (28%)          42 (36%)            34 (29%)
   Descending to sigmoid colon                                         144 (31%)         29 (25%)                                 44 (36%)          35 (30%)            36 (31%)
   Rectum                                                              97 (21%)          29 (25%)                                 22 (18%)          20 (17%)            26 (22%)
  Tumor differentiation                                                                                                                                                 
   Well to moderate                                                    431 (92%)         109 (96%)                                106 (88%)         107 (92%)           109 (93%)
   Poor                                                                37 (7.9%)         5 (4.4%)                                 15 (12%)          9 (7.8%)            8 (6.8%)
  AJCC disease stage                                                                                                                                                    
   I                                                                   115 (26%)         29 (27%)                                 21 (19%)          36 (33%)            29 (26%)
   II                                                                  158 (36%)         29 (27%)                                 44 (40%)          38 (35%)            47 (42%)
   III                                                                 138 (31%)         38 (35%)                                 37 (34%)          31 (28%)            32 (29%)
   IV                                                                  29 (6.6%)         13 (12%)                                 8 (7.3%)          5 (4.6%)            3 (2.7%)
  MSI status                                                                                                                                                            
   Non-MSI-high                                                        386 (83%)         92 (81%)                                 96 (81%)          99 (85%)            99 (84%)
   MSI-high                                                            81 (17%)          22 (19%)                                 23 (19%)          17 (15%)            19 (16%)
  CIMP status                                                                                                                                                           
   Low/negative                                                        384 (82%)         87 (78%)                                 99 (83%)          101 (86%)           97 (83%)
   High                                                                82 (18%)          25 (22%)                                 21 (18%)          16 (14%)            20 (17%)
  Mean LINE-1 methylation level ± SD (%)                               61.1 ± 9.6        60.5 ± 10.0                              60.4 ± 9.3        60.8 ± 10.1         62.9 ± 9.0
  *KRAS* mutation                                                                                                                                                       
   Wild-type                                                           269 (58%)         64 (56%)                                 65 (55%)          72 (63%)            68 (58%)
   Mutant                                                              195 (42%)         50 (44%)                                 53 (45%)          43 (37%)            49 (42%)
  *BRAF* mutation                                                                                                                                                       
   Wild-type                                                           400 (86%)         96 (85%)                                 105 (88%)         100 (88%)           99 (85%)
   Mutant                                                              64 (14%)          17 (15%)                                 15 (13%)          14 (12%)            18 (15%)
  *PIK3CA* mutation                                                                                                                                                     
   Wild-type                                                           353 (82%)         88 (87%)                                 88 (81%)          91 (83%)            86 (77%)
   Mutant                                                              77 (18%)          13 (13%)                                 20 (19%)          19 (17%)            25 (23%)
  Nuclear CTNNB1 (beta-catenin) expression                                                                                                                              
   Negative                                                            238 (53%)         62 (56%)                                 60 (51%)          59 (54%)            57 (50%)
   Positive                                                            213 (47%)         48 (44%)                                 58 (49%)          51 (46%)            56 (50%)
  PTGS2 (cyclooxygenase-2) expression                                                                                                                                   
   Negative                                                            179 (38%)         48 (42%)                                 44 (36%)          45 (38%)            42 (36%)
   Positive                                                            291 (62%)         66 (58%)                                 77 (64%)          72 (62%)            76 (64%)
  *IRS1* expression                                                                                                                                                     
   Negative/low                                                        289 (70%)         74 (70%)                                 83 (76%)          64 (65%)            68 (67%)
   High                                                                125 (30%)         31 (30%)                                 26 (24%)          35 (35%)            33 (33%)
  CD3^^+^^ cell density                                                                                                                                                 
   Quartile 1 (lowest)                                                 111 (25%)         32 (29%)                                 28 (25%)          29 (26%)            22 (20%)
   Quartile 2                                                          111 (25%)         32 (29%)                                 18 (16%)          32 (28%)            29 (27%)
   Quartile 3                                                          112 (25%)         17 (15%)                                 37 (33%)          26 (23%)            32 (29%)
   Quartile 4 (highest)                                                111 (25%)         29 (26%)                                 30 (27%)          26 (23%)            26 (24%)
  CD8^^+^^ cell density                                                                                                                                                 
   Quartile 1 (lowest)                                                 110 (25%)         32 (30%)                                 28 (25%)          31 (28%)            19 (18%)
   Quartile 2                                                          109 (25%)         31 (29%)                                 22 (20%)          29 (26%)            27 (25%)
   Quartile 3                                                          109 (25%)         20 (19%)                                 27 (24%)          28 (25%)            34 (32%)
   Quartile 4 (highest)                                                109 (25%)         24 (22%)                                 34 (31%)          24 (21%)            27 (25%)
  CD45RO^^+^^ cell density                                                                                                                                              
   Quartile 1 (lowest)                                                 113 (25%)         28 (26%)                                 27 (23%)          35 (31%)            23 (21%)
   Quartile 2                                                          113 (25%)         32 (29%)                                 33 (28%)          24 (21%)            24 (21%)
   Quartile 3                                                          113 (25%)         27 (25%)                                 29 (25%)          26 (23%)            31 (28%)
   Quartile 4 (highest)                                                112 (25%)         22 (20%)                                 28 (24%)          28 (25%)            34 (30%)
  FOXP3^^+^^ cell density                                                                                                                                               
   Quartile 1 (lowest)                                                 107 (25%)         31 (30%)                                 27 (24%)          24 (24%)            25 (24%)
   Quartile 2                                                          106 (25%)         27 (26%)                                 39 (34%)          18 (18%)            22 (21%)
   Quartile 3                                                          106 (25%)         22 (21%)                                 24 (21%)          25 (25%)            35 (33%)
   Quartile 4 (highest)                                                107 (25%)         24 (23%)                                 24 (21%)          35 (34%)            24 (23%)

Percentage (%) indicates the proportion of cases with a specific clinical, pathological, or molecular characteristic of colorectal cancer cases in all cases or in strata of quartiles of postdiagnosis physical activity levels. AJCC = American Joint Committee on Cancer; CIMP = CpG island methylator phenotype; HPFS = Health Professionals Follow-up Study; LINE-1 = long interspersed nucleotide element-1; METS = metabolic equivalent task score; MSI = microsatellite instability; NHS = Nurses' Health Study.

###### 

Colorectal cancer mortality according to postdiagnosis physical activity levels in all cases or in strata of quartiles of T cell densities

                                                             Colorectal cancer-specific mortality HR for a quartile-unit increase of postdiagnosis physical activity levels   Overall mortality HR for a quartile-unit increase of postdiagnosis physical activity levels                                                     
  ---------------------------------------------------- ----- ---------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- --------------------- ----- --------------------- ---------------------
  All colorectal cancer cases                          470   100                                                                                                              0.77 (0.64 to 0.92)                                                                           0.78 (0.64 to 0.95)   275   0.77 (0.69 to 0.86)   0.83 (0.75 to 0.93)
  CD3^+^ cell density                                                                                                                                                                                                                                                                                                         
   Quartile 1 (lowest)                                 111   30                                                                                                               0.61 (0.42 to 0.88)                                                                           0.56 (0.38 to 0.83)   69    0.75 (0.59 to 0.95)   0.76 (0.62 to 0.93)
   Quartile 2                                          111   23                                                                                                               0.78 (0.53 to 1.15)                                                                           0.80 (0.54 to 1.18)   64    0.68 (0.55 to 0.84)   0.72 (0.58 to 0.89)
   Quartile 3                                          112   25                                                                                                               0.75 (0.49 to 1.14)                                                                           0.73 (0.47 to 1.11)   68    0.80 (0.63 to 1.02)   0.83 (0.65 to 1.06)
   Quartile 4 (highest)                                111   15                                                                                                               1.04 (0.73 to 1.49)                                                                           1.14 (0.79 to 1.65)   60    0.85 (0.67 to 1.08)   0.96 (0.76 to 1.21)
   *P*~interaction~[‡](#tblfn4){ref-type="table-fn"}                                                                                                                          .004                                                                                          \<.001                      .35                   .17
  CD8^+^ cell density                                                                                                                                                                                                                                                                                                         
   Quartile 1 (lowest)                                 110   34                                                                                                               0.67 (0.48 to 0.92)                                                                           0.66 (0.47 to 0.94)   66    0.72 (0.56 to 0.92)   0.78 (0.59 to 1.02)
   Quartile 2                                          109   23                                                                                                               0.84 (0.57 to 1.23)                                                                           0.81 (0.56 to 1.18)   65    0.81 (0.65 to 1.00)   0.80 (0.65 to 0.99)
   Quartile 3                                          109   18                                                                                                               0.58 (0.37 to 0.90)                                                                           0.56 (0.33 to 0.95)   59    0.62 (0.49 to 0.79)   0.75 (0.59 to 0.95)
   Quartile 4 (highest)                                109   19                                                                                                               1.03 (0.71 to 1.51)                                                                           1.02 (0.67 to 1.56)   64    0.87 (0.69 to 1.10)   0.86 (0.70 to 1.05)
   *P*~interaction~‡                                                                                                                                                          .060                                                                                          .14                         .22                   .45
  CD45RO^+^ cell density                                                                                                                                                                                                                                                                                                      
   Quartile 1 (lowest)                                 113   33                                                                                                               0.95 (0.69 to 1.31)                                                                           0.86 (0.62 to 1.19)   73    0.73 (0.57 to 0.93)   0.77 (0.62 to 0.95)
   Quartile 2                                          113   34                                                                                                               0.70 (0.49 to 1.01)                                                                           0.64 (0.44 to 0.95)   69    0.77 (0.60 to 0.97)   0.79 (0.62 to 0.99)
   Quartile 3                                          113   19                                                                                                               0.61 (0.41 to 0.91)                                                                           0.65 (0.42 to 1.02)   63    0.74 (0.59 to 0.91)   0.80 (0.65 to 1.00)
   Quartile 4 (highest)                                112   10                                                                                                               0.87 (0.46 to 1.63)                                                                           0.88 (0.44 to 1.72)   60    0.82 (0.66 to 1.03)   0.91 (0.74 to 1.13)
   *P*~interaction~[‡](#tblfn4){ref-type="table-fn"}                                                                                                                          .81                                                                                           .84                         .76                   .80
  FOXP3^+^ cell density                                                                                                                                                                                                                                                                                                       
   Quartile 1 (lowest)                                 107   32                                                                                                               0.71 (0.50 to 1.00)                                                                           0.75 (0.51 to 1.10)   76    0.67 (0.53 to 0.84)   0.74 (0.58 to 0.94)
   Quartile 2                                          106   23                                                                                                               0.69 (0.48 to 0.99)                                                                           0.72 (0.48 to 1.08)   67    0.71 (0.58 to 0.87)   0.75 (0.61 to 0.92)
   Quartile 3                                          106   20                                                                                                               0.94 (0.62 to 1.44)                                                                           1.02 (0.68 to 1.51)   56    0.98 (0.75 to 1.27)   1.06 (0.85 to 1.33)
   Quartile 4 (highest)                                107   13                                                                                                               0.66 (0.42 to 1.03)                                                                           0.64 (0.40 to 1.03)   49    0.73 (0.56 to 0.94)   0.77 (0.61 to 0.98)
   *P*~interaction~[‡](#tblfn4){ref-type="table-fn"}                                                                                                                          .46                                                                                           .33                         .73                   .31

IPW was applied to reduce a bias due to the availability of questionnaire data after cancer diagnosis (see Statistical Analysis subsection for details). CI = confidence interval; HR = hazard ratio; IPW = inverse probability weighting.

The multivariable sex-stratified IPW-adjusted Cox regression model initially included age, year of diagnosis, family history of colorectal cancer, body mass index, prediagnosis physical activity, tumor location, tumor differentiation, disease stage, microsatellite instability, CpG island methylator phenotype, long interspersed nucleotide element-1 methylation level, *KRAS* mutation, *BRAF* mutation, *PIK3CA* mutation, nuclear CTNNB1 (beta-catenin) expression, PTGS2 (cyclooxygenase-2) expression, and *IRS1* expression. A backward elimination with a threshold of *P* equal to .05 was used to select variables for the final models. The variables that remained in the final models for analyses stratified by CD3^+^ cell density are described in Appendix Table A2.

*P* ~interaction~ was calculated using the Wald test for the cross-product of postdiagnosis physical activity levels (the median value of each decile category) and each T cell subset (the median value of each decile category) in the sex-stratified IPW-adjusted Cox regression model.

In our primary hypothesis testing, the association of postdiagnosis physical activity levels and colorectal cancer-specific mortality differed by CD3^+^ cell density (*P*~interaction~ \< .001; with the α level of 0.005; [Table 2](#pky058-T2){ref-type="table"} and [Supplementary Table 2](#sup1){ref-type="supplementary-material"}, available online). The multivariable-adjusted HRs of colorectal cancer-specific mortality for a quartile-unit increase in postdiagnosis physical activity levels were 0.56 (95% confidence interval \[CI\] = 0.38 to 0.83) in the lowest quartile of CD3^+^ cell density and 1.14 (95% CI = 0.79 to 1.65) in the highest quartile of CD3^+^ cell density. The differential prognostic association was similarly observed in women and men, although statistical power was limited in each subgroup ([Table 3](#pky058-T3){ref-type="table"}). [Figure 1](#pky058-F1){ref-type="fig"} shows IPW-adjusted Kaplan-Meier survival curves of colorectal cancer-specific survival according to tertiles of postdiagnosis physical activity levels, and [Table 4](#pky058-T4){ref-type="table"} shows HRs of cancer-specific mortality in each category of postdiagnosis physical activity levels. Taking into account the small number of events in each category, we used tertiles of postdiagnosis physical activity levels for these analyses. Considering the influence of arbitrary cutoff points, we entered postdiagnosis physical activity levels as a continuous variable into the models and obtained similar results ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}, available online). When we excluded stage IV patients ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}, available online) or patients who died within 6 months of the first postdiagnosis questionnaire return (n = 12, data not shown), we observed a similar interactive prognostic association of postdiagnosis physical activity levels and CD3^+^ cell density (*P*~interaction~ \< .001). We did not observe any statistically significant interaction of postdiagnosis physical activity levels with densities of CD8^+^ cells, CD45RO^+^ cells, or FOXP3^+^ cells (*P*~interaction~ \> .13; [Table 2](#pky058-T2){ref-type="table"}).

###### 

Colorectal cancer mortality according to postdiagnosis physical activity levels in all cases or in strata of quartiles of CD3^+^ cell density by sex

                                                              Colorectal cancer-specific mortality HR for a quartile-unit increase of postdiagnosis physical activity levels   Overall mortality HR for a quartile-unit increase of postdiagnosis physical activity levels                                                     
  ----------------------------------------------------- ----- ---------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- --------------------- ----- --------------------- ---------------------
  Female                                                                                                                                                                                                                                                                                                                       
   All colorectal cancer cases                          252   55                                                                                                               0.72 (0.55 to 0.93)                                                                           0.72 (0.55 to 0.94)   134   0.68 (0.58 to 0.80)   0.68 (0.57 to 0.80)
   CD3^+^ cell density                                                                                                                                                                                                                                                                                                         
    Quartile 1 (lowest)                                 56    15                                                                                                               0.49 (0.27 to 0.87)                                                                           0.45 (0.25 to 0.82)   27    0.52 (0.34 to 0.80)   0.57 (0.35 to 0.91)
    Quartile 2                                          61    14                                                                                                               0.78 (0.47 to 1.29)                                                                           0.86 (0.50 to 1.48)   30    0.56 (0.39 to 0.79)   0.55 (0.39 to 0.77)
    Quartile 3                                          65    15                                                                                                               0.90 (0.55 to 1.48)                                                                           0.74 (0.44 to 1.25)   40    0.92 (0.69 to 1.22)   0.86 (0.65 to 1.15)
    Quartile 4 (highest)                                53    6                                                                                                                0.55 (0.38 to 0.80)                                                                           0.66 (0.44 to 1.00)   29    0.67 (0.50 to 0.91)   0.74 (0.53 to 1.02)
    *P*~interaction~[‡](#tblfn7){ref-type="table-fn"}                                                                                                                          .071                                                                                          .11                         .60                   .37
  Male                                                                                                                                                                                                                                                                                                                         
   All colorectal cancer cases                          218   45                                                                                                               0.83 (0.65 to 1.07)                                                                           0.69 (0.50 to 0.96)   141   0.87 (0.75 to 1.01)   0.98 (0.85 to 1.13)
   CD3^+^ cell density                                                                                                                                                                                                                                                                                                         
    Quartile 1 (lowest)                                 55    15                                                                                                               0.73 (0.46 to 1.15)                                                                           0.64 (0.39 to 1.05)   42    0.90 (0.70 to 1.15)   0.93 (0.74 to 1.17)
    Quartile 2                                          50    9                                                                                                                0.77 (0.43 to 1.39)                                                                           0.60 (0.32 to 1.13)   34    0.79 (0.62 to 1.01)   0.90 (0.70 to 1.15)
    Quartile 3                                          47    10                                                                                                               0.50 (0.23 to 1.09)                                                                           0.55 (0.26 to 1.20)   28    0.63 (0.41 to 0.99)   0.82 (0.53 to 1.26)
    Quartile 4 (highest)                                58    9                                                                                                                1.58 (0.98 to 2.55)                                                                           1.55 (0.86 to 2.80)   31    1.08 (0.76 to 1.54)   1.18 (0.84 to 1.65)
    *P*~interaction~‡                                                                                                                                                          .001                                                                                          \<.001                      .25                   .27

IPW was applied to reduce a bias due to the availability of questionnaire data after cancer diagnosis (see "Statistical Analysis" subsection for details). CI = confidence interval; HR = hazard ratio; IPW = inverse probability weighting.

The multivariable IPW-adjusted Cox regression model initially included age, year of diagnosis, family history of colorectal cancer, body mass index, prediagnosis physical activity, tumor location, tumor differentiation, disease stage, microsatellite instability, CpG island methylator phenotype, long interspersed nucleotide element-1 methylation level, *KRAS* mutation, *BRAF* mutation, *PIK3CA* mutation, nuclear CTNNB1 (beta-catenin) expression, PTGS2 (cyclooxygenase-2) expression, and *IRS1* expression. A backward elimination with a threshold of *P* equal to .05 was used to select variables for the final models.

*P* ~interaction~ was calculated using the Wald test for the cross-product of postdiagnosis physical activity levels (the median value of each decile category) and each T cell subset (the median value of each decile category) in the IPW-adjusted Cox regression model.

###### 

Colorectal cancer mortality according to tertiles (\<4.5, 4.5 to 17.6, and ≥17.7 METS-h/wk) of postdiagnosis physical activity levels in strata of CD3^+^ cell density

                                                             Colorectal cancer-specific mortality HR   Overall mortality HR                                                   
  ---------------------------------------------------- ---- ----------------------------------------- ---------------------- --------------------- ---- --------------------- ---------------------
  CD3^+^ cell-low‡                                                                                                                                                            
   Postdiagnosis physical activity                                                                                                                                            
    \<4.5 METS-h/wk                                     84                     29                          1 (referent)          1 (referent)       59      1 (referent)          1 (referent)
    4.5 to 17.6 METS-h/wk                               66                     11                      0.42 (0.21 to 0.84)    0.37 (0.18 to 0.77)   34   0.53 (0.34 to 0.81)   0.54 (0.35 to 0.84)
    ≥17.7 METS-h/wk                                     72                     13                      0.44 (0.23 to 0.84)    0.33 (0.16 to 0.67)   40   0.53 (0.35 to 0.79)   0.53 (0.35 to 0.79)
  CD3^+^ cell-high[‡](#tblfn10){ref-type="table-fn"}                                                                                                                          
   Postdiagnosis physical activity                                                                                                                                            
    \<4.5 METS-h/wk                                     62                     13                          1 (referent)          1 (referent)       43      1 (referent)          1 (referent)
    4.5 to 17.6 METS-h/wk                               86                     13                      0.62 (0.29 to 1.34)    0.58 (0.27 to 1.24)   43   0.58 (0.38 to 0.88)   0.53 (0.35 to 0.81)
    ≥17.7 METS-h/wk                                     75                     14                      0.75 (0.36 to 1.57)    0.62 (0.30 to 1.29)   42   0.63 (0.41 to 0.96)   0.72 (0.47 to 1.11)

IPW was applied to reduce a bias due to the availability of questionnaire data after cancer diagnosis (see "Statistical Analysis" subsection for details). CI = confidence interval; HR = hazard ratio; IPW = inverse probability weighting; METS = metabolic equivalent task score.

The multivariable sex-stratified IPW-adjusted Cox regression model initially included age, year of diagnosis, family history of colorectal cancer, body mass index, prediagnosis physical activity, tumor location, tumor differentiation, disease stage, microsatellite instability, CpG island methylator phenotype, long interspersed nucleotide element-1 methylation level, *KRAS* mutation, *BRAF* mutation, *PIK3CA* mutation, nuclear CTNNB1 (beta-catenin) expression, PTGS2 (cyclooxygenase-2) expression, and *IRS1* expression. A backward elimination with a threshold of *P* equal to .05 was used to select variables for the final models.

CD3^+^ cell density was categorized as low vs high by the median value.

![Inverse probability weighting-adjusted Kaplan-Meier curves of colorectal cancer-specific survival and overall survival according to tertiles of postdiagnosis physical activity levels (\<4.5 vs 4.5 to 17.6 vs ≥17.7 METS-h/wk) in strata of CD3^+^ cell density. The *P* values were calculated using the weighted log-rank test (two-sided). **A and B**), CD3^+^ cell-low patients; **C and D**), CD3^+^ cell-high patients. METS = metabolic equivalent task score.](pky058f1){#pky058-F1}

Our previous studies have suggested that the association of postdiagnosis physical activity levels with colorectal cancer survival might differ by nuclear CTNNB1 (42), PTGS2 (39), or *IRS1* expression status ([@pky058-B40]). Therefore, we performed secondary analyses stratified jointly by CD3^+^ cell density with nuclear CTNNB1, PTGS2, or *IRS1* expression status ([Table 5](#pky058-T5){ref-type="table"}). Although statistical power was limited, there appeared to be a differential prognostic association by CD3^+^ cell density across nuclear CTNNB1 expression status and in PTGS2-positive or *IRS1*-negative cases.

###### 

Colorectal cancer mortality according to postdiagnosis physical activity levels in strata of combined CD3^+^ cell density and nuclear CTNNB1 (beta-catenin) expression, PTGS2 (cyclooxygenase-2) expression, or *IRS1* expression status

                                                               Colorectal cancer-specific mortality HR for a quartile-unit increase of postdiagnosis physical activity levels   Overall mortality HR for a quartile-unit increase of postdiagnosis physical activity levels                                                    
  ------------------------------------------------------ ----- ---------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- --------------------- ---- --------------------- ---------------------
  Nuclear CTNNB1 (beta-catenin) expression                                                                                                                                                                                                                                                                                     
   Negative                                                                                                                                                                                                                                                                                                                    
    CD3^+^ cell-low[‡](#tblfn13){ref-type="table-fn"}    109   25                                                                                                               0.60 (0.39 to 0.91)                                                                           0.57 (0.37 to 0.88)   65   0.58 (0.46 to 0.74)   0.61 (0.49 to 0.76)
    CD3^+^ cell-high[‡](#tblfn13){ref-type="table-fn"}   117   22                                                                                                               0.82 (0.58 to 1.16)                                                                           0.81 (0.57 to 1.14)   67   0.79 (0.63 to 1.00)   0.89 (0.72 to 1.10)
   Positive                                                                                                                                                                                                                                                                                                                    
    CD3^+^ cell-low[‡](#tblfn13){ref-type="table-fn"}    106   28                                                                                                               0.76 (0.55 to 1.06)                                                                           0.74 (0.52 to 1.05)   66   0.79 (0.64 to 0.98)   0.87 (0.70 to 1.07)
    CD3^+^ cell-high[‡](#tblfn13){ref-type="table-fn"}   97    16                                                                                                               0.93 (0.55 to 1.58)                                                                           1.03 (0.62 to 1.73)   55   0.91 (0.70 to 1.18)   0.96 (0.75 to 1.24)
  PTGS2 (cyclooxygenase-2) expression                                                                                                                                                                                                                                                                                          
   Negative                                                                                                                                                                                                                                                                                                                    
    CD3^+^ cell-low[‡](#tblfn13){ref-type="table-fn"}    74    14                                                                                                               0.62 (0.38 to 1.02)                                                                           0.60 (0.37 to 0.99)   43   0.71 (0.55 to 0.91)   0.71 (0.54 to 0.94)
    CD3^+^ cell-high[‡](#tblfn13){ref-type="table-fn"}   90    14                                                                                                               0.58 (0.36 to 0.96)                                                                           0.55 (0.33 to 0.90)   51   0.69 (0.53 to 0.89)   0.78 (0.60 to 1.02)
   Positive                                                                                                                                                                                                                                                                                                                    
    CD3^+^ cell-low[‡](#tblfn13){ref-type="table-fn"}    148   39                                                                                                               0.71 (0.52 to 0.96)                                                                           0.61 (0.44 to 0.86)   90   0.71 (0.58 to 0.86)   0.74 (0.61 to 0.89)
    CD3^+^ cell-high[‡](#tblfn13){ref-type="table-fn"}   133   26                                                                                                               1.11 (0.78 to 1.58)                                                                           1.06 (0.73 to 1.55)   77   0.95 (0.77 to 1.18)   1.01 (0.82 to 1.24)
  *IRS1* expression                                                                                                                                                                                                                                                                                                            
   Negative/low                                                                                                                                                                                                                                                                                                                
    CD3^+^ cell-low[‡](#tblfn13){ref-type="table-fn"}    136   38                                                                                                               0.62 (0.44 to 0.86)                                                                           0.60 (0.42 to 0.86)   89   0.68 (0.56 to 0.82)   0.71 (0.58 to 0.86)
    CD3^+^ cell-high[‡](#tblfn13){ref-type="table-fn"}   144   19                                                                                                               0.82 (0.53 to 1.26)                                                                           0.76 (0.49 to 1.19)   79   0.87 (0.71 to 1.08)   0.91 (0.74 to 1.12)
   High                                                                                                                                                                                                                                                                                                                        
    CD3^+^ cell-low[‡](#tblfn13){ref-type="table-fn"}    57    7                                                                                                                1.73 (1.03 to 2.90)                                                                           1.57 (0.93 to 2.64)   30   0.98 (0.72 to 1.34)   0.93 (0.72 to 1.20)
    CD3^+^ cell-high[‡](#tblfn13){ref-type="table-fn"}   62    19                                                                                                               1.01 (0.69 to 1.46)                                                                           1.18 (0.82 to 1.69)   40   0.80 (0.61 to 1.07)   0.89 (0.67 to 1.19)

IPW was applied to reduce a bias due to the availability of questionnaire data after cancer diagnosis (see "Statistical Analysis" subsection for details). CI = confidence interval; HR = hazard ratio; IPW = inverse probability weighting.

The multivariable sex-stratified IPW-adjusted Cox regression model initially included age, year of diagnosis, family history of colorectal cancer, body mass index, prediagnosis physical activity, tumor location, tumor differentiation, disease stage, microsatellite instability, CpG island methylator phenotype, long interspersed nucleotide element-1 methylation level, *KRAS* mutation, *BRAF* mutation, *PIK3CA* mutation, nuclear CTNNB1 expression (except for CTNNB1-stratified analyses), PTGS2 expression (except for PTGS2-stratified analyses), and *IRS1* expression (except for *IRS1*-stratified analyses). A backward elimination with a threshold of *P* equal to .05 was used to select variables for the final models.

CD3^+^ cell density was categorized as low vs high by the median value.

In our exploratory analysis, there were no statistically significant interactions between postdiagnosis physical activity levels and any of the lymphocytic reaction patterns examined ([Supplementary Table 5](#sup1){ref-type="supplementary-material"}, available online).

Discussion
==========

Using two large prospective cohort studies, we tested the hypothesis that the association of postdiagnosis physical activity levels with colorectal cancer survival might differ by levels of tumor-infiltrating T cell subsets (CD3^+^ cells, CD8^+^ cells, CD45RO^+^ cells, or FOXP3^+^ cells). We found a stronger prognostic association of postdiagnosis physical activity levels for colorectal cancer accompanied by lower levels of CD3^+^ pan-T cells than for cancer accompanied by higher levels of CD3^+^ cells. Our results support an interactive effect of physical activity and immune status in the regulation of colorectal cancer progression. A future study is warranted to examine how the association between physical activity levels and colorectal cancer incidence may differ by tumor-infiltrating T cells.

Cancer immunotherapies such as immune checkpoint inhibitors have shown considerable promise with durable response ([@pky058-B8],[@pky058-B10]). In colorectal carcinomas, clinical benefits from blockade therapies targeting the *CD274* (PD-L1)-*PDCD1* (PD-1) axis have shown to be greater for MSI-high tumors that are characterized by higher levels of mutation load and immunogenic neoantigens ([@pky058-B9]). However, a subset of MSI-high colorectal cancer responds poorly to immunotherapies. Intensity of the potential anti-tumor immune response is also a major determinant of the response to immunotherapies in colorectal cancer, which is affected by multiple endogenous and exogenous factors, including the gut microbiota ([@pky058-B53]). In this setting, there is an increasing need for integrative analyses of lifestyle factors, tumor features, and host immunity ([@pky058-B6]). A better understanding of the tumor-immune microenvironment would help us to optimize preventive and treatment strategies through immune modulation.

Evidence indicates the role of energy balance in carcinogenesis ([@pky058-B56]), and every tumor differs from other tumors ([@pky058-B57]). In the current study, we found a differential prognostic association of postdiagnosis physical activity levels by CD3^+^ cell density in colorectal carcinoma tissue. None of the more specific subsets of T cells statistically significantly modified the prognostic association of physical activity. This may indicate that, collectively, the density of pan-T cells (but not specific types of T cells) may indeed modify the prognostic effect of physical activity or that the measurements of the other specific markers of T cells may need further refinements. In addition, the density of CD3^+^ pan-T cells alone may be a potentially useful biomarker to identify the subpopulation that benefits more from postdiagnosis physical activity. To our knowledge, this is the first exploratory analysis on the interaction between postdiagnosis physical activity and immune response for colorectal cancer mortality. Therefore, our findings need to be validated in independent cohorts. Studies indicate that exercise can alter the number and function of circulating immune cells, including CD3^+^ cells, *CD4*^+^ cells, CD8^+^ cells, macrophages, and natural killer cells in healthy populations ([@pky058-B29]). Studies suggest that higher physical activity may increase plasma levels of *ADIPOQ* (adiponectin) ([@pky058-B58]). *ADIPOQ* can suppress inflammatory changes in the tumor microenvironment ([@pky058-B61],[@pky058-B62]). Furthermore, higher levels of *IL6* released from skeletal muscle during exercise may increase levels of cytokines (eg, *IL1R1* and *IL10*) and cortisol, both of which exert anti-inflammatory properties ([@pky058-B29],[@pky058-B63]). Preclinical studies suggest that exercise may increase circulating lymphocytes, promote the infiltration of natural killer cells to tumors, and increase apoptosis of cancer cells ([@pky058-B29]). In mouse models for colorectal cancer, exercise was associated with higher expression of cytotoxic T cell marker genes in intestinal mucosal tissue ([@pky058-B32]). Our population-based data support these mechanistic data, providing evidence for the immunomodulatory effects of physical activity in the regulation of colorectal cancer progression in humans. In the present study, there appeared to be no dose-response relationship between postdiagnosis physical activity levels and patient survival in CD3^+^ cell-low tumors. This may suggest a possibility of a threshold effect of physical activity for its immunomodulatory anti-tumor influence. However, we have been cautious in interpreting an individual HR estimate comparing each category of physical activity (to the referent category) in each stratum of patients according to T cell infiltrates, considering multiple hypothesis testing in such assessments. Further research is needed to assess potential dose-response effects of physical activity levels on colorectal cancer mortality in specific tumor types.

There are limitations in the current study. First, limited data on cancer treatments are available in our study populations. However, it was unlikely that treatment strategies were determined by levels of T cell densities, because attending physicians did not have access to such information. Second, the differential availability of questionnaire return for physical activity assessment after colorectal cancer diagnosis might have caused a bias. Thus, we used the IPW method in all survival analyses to reduce this potential bias. Third, available data on cancer recurrence were limited, but given the long follow-up duration of censored cases, colorectal cancer-specific mortality was considered as a reasonable surrogate for colorectal cancer-specific outcomes.

Strengths of the present study include the use of a molecular pathological epidemiology ([@pky058-B66]) database derived from two large prospective cohort studies, which included data on lifestyle factors and tumor molecular and immune characteristics. This integrated database allowed us to examine the interaction between postdiagnosis physical activity levels and tumor-infiltrating T cells while adjusting for a variety of potential confounders. In addition, this database enabled us to adjust for long-term physical activity levels before cancer diagnosis. Participants were enrolled at a large number of hospitals in diverse locations across the United States, which might improve the generalizability of our findings.

The current study suggests that the association of higher levels of postdiagnosis physical activity with better prognosis is stronger for colorectal carcinomas with lower CD3^+^ cell density than for carcinomas with higher CD3^+^ cell density. The present study provides evidence for a potential interaction between physical activity and anti-tumor immune response in suppressing colorectal cancer progression. Our findings suggest that the measurement of immune response based on densities of CD3^+^ in tumor tissue at diagnosis may help select patients who can gain the most benefit from exercise.
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